By Fineline Cube 
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics, Inc. (CGEM). The deal grants Cullinan exclusive development, manufacturing, and commercialization rights to Genrix Bio’s GR1803 outside Greater China (including Hong Kong, Macau, and Taiwan). Genrix Bio retains all rights in Greater China and plans to explore the use of GR1803 in autoimmune diseases within mainland China, conducting clinical trials and providing clinical data to Cullinan under a paid licensing arrangement.
Financial Terms
Under the agreement, Cullinan will pay up to USD 712 million in total, including a USD 20 million upfront payment, up to USD 292 million in development and regulatory milestone payments, and up to USD 400 million in sales-based milestone payments. Additionally, Cullinan will pay tiered royalties on net sales in the licensed territories, reaching up to the mid-double-digit percentage range.
GR1803 Technology and Development
GR1803 is a bispecific antibody targeting both BCMA and CD3. It redirects cytotoxic T cells to BCMA-expressing cells, with high affinity for BCMA and low affinity for CD3 (100-fold higher selectivity for BCMA). This design ensures effective T-cell recruitment and activation while minimizing off-target effects. GR1803 received clinical trial approval from China’s NMPA for multiple myeloma (MM) in January 2022 and Breakthrough Therapy Designation (BTD) in August 2023. It is currently in a Phase II study for relapsed/refractory MM in China.-Fineline Info & Tech